These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 2800585)

  • 1. Pharmacoeconomic research and clinical trials: concepts and issues.
    Bootman JL; Larson LN; McGhan WF; Townsend RJ
    DICP; 1989 Sep; 23(9):693-7. PubMed ID: 2800585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacoeconomics: an emerging discipline.
    Letizia C
    Qual Assur; 1995 Mar; 4(1):68-74. PubMed ID: 8520866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishing value through pharmacoeconomics: the emerging third objective in clinical trials.
    Boyer JG; Pathak DS
    Top Hosp Pharm Manage; 1994 Jan; 13(4):1-10. PubMed ID: 10130679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoeconomics.
    Ahuja J; Gupta M; Gupta AK; Kohli K
    Natl Med J India; 2004; 17(2):80-3. PubMed ID: 15141600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacoeconomic analysis in Saudi Arabia: an overdue agenda item for action.
    Al-Jazairi AS; Al-Qadheeb NS; Ajlan A
    Ann Saudi Med; 2011; 31(4):335-41. PubMed ID: 21808106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacoeconomics of dementia.
    Whitehouse PJ
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 5():S22-32; discussion S32-3. PubMed ID: 9348424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protocol-driven costs in trial-based pharmacoeconomic analyses.
    Gandjour A
    Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):673-5. PubMed ID: 22098282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pitfalls associated with commonly used methods for pharmacoeconomic analyses.
    Klepser DG
    Pharmacotherapy; 2002 Feb; 22(2 Pt 2):35S-38S. PubMed ID: 11837545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guidelines for performing a pharmacoeconomic analysis.
    Jolicoeur LM; Jones-Grizzle AJ; Boyer JG
    Am J Hosp Pharm; 1992 Jul; 49(7):1741-7. PubMed ID: 1621734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The rationale of pharmacoeconomic analysis in rheumatologic indications.
    Turchetti G; Scalone L; Della Casa Alberighi O; Mosca M; Montella S; Cortesi PA; Mantovani LG
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S64-71. PubMed ID: 23072796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacoeconomics. I].
    Kolár J
    Ceska Slov Farm; 1997 Feb; 46(1):9-13. PubMed ID: 9221090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview of pharmacoeconomics and pharmaceutical outcomes evaluations.
    Reeder CE
    Am J Health Syst Pharm; 1995 Oct; 52(19 Suppl 4):S5-8. PubMed ID: 8846244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next-generation multiple myeloma treatment: a pharmacoeconomic perspective.
    Rajkumar SV; Harousseau JL
    Blood; 2016 Dec; 128(24):2757-2764. PubMed ID: 27742709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methodological and conduct principles for pharmacoeconomic research. Pharmaceutical Research and Manufacturers of America.
    Clemens K; Townsend R; Luscombe F; Mauskopf J; Osterhaus J; Bobula J
    Pharmacoeconomics; 1995 Aug; 8(2):169-74. PubMed ID: 10155611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The future of pharmacoeconomics: bridging science and practice.
    Drummond MF
    Clin Ther; 1996; 18(5):969-78; discussion 968. PubMed ID: 8930435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoeconomics and formulary decision making.
    Sanchez LA
    Pharmacoeconomics; 1996; 9 Suppl 1():16-25. PubMed ID: 10160112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical issues in conducting pharmacoeconomic studies.
    Rajagopalan R; Kallal JE; Fowler JF; Sherertz EF
    Clin Ther; 1996; 18(6):1298-306. PubMed ID: 9001844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions.
    Lipsy RJ
    Pharmacoeconomics; 1992 Apr; 1(4):265-81. PubMed ID: 10147017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluations during early (phase II) drug development: a role for clinical trial simulations?
    Hughes DA; Walley T
    Pharmacoeconomics; 2001; 19(11):1069-77. PubMed ID: 11735674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.